Champions Oncology, Inc. (CSBR) AI Stock Analysis

Champions Oncology, Inc. specializes in technology solutions and products to personalize the development and application of oncology drugs. Its primary offering is the Tumorgraft Technology Platform, which implants human tumors into immune-deficient mice to create personalized treatment strategies. Through this platform, it also provides Translational Oncology Solutions to pharmaceutical and biotechnology companies to enhance the drug development process. Additionally, the company provides Lumin Bioinformatics, a software platform and data tool that provides insights through annual subscription services. Headquartered in Hackensack, New Jersey, the company markets its offerings through internet channels, word of mouth, and a dedicated sales force.

Champions Oncology expanded revenue at a 5-year CAGR of 7.7% from FY2021 to FY2026. In FY2026, revenue rose 4.4% to $59.4M, slowing from 13.5% growth in FY2025. Gross margin narrowed from 50.1% in FY2025 to 48.0% in FY2026. The company recorded an operating margin of -1.9% and net income of -$1.2M in FY2026, after generating net income of $4.7M in FY2025. In the latest quarter ending July 31, 2026, quarterly revenue increased 8.8% year-over-year, while quarterly earnings dropped 61.1%. Over the trailing twelve months, revenue reached $60.7M with an operating margin of -2.7% and diluted EPS of -$0.07.

As of July 31, 2026, Champions Oncology held $4.4M in cash and short-term investments against total debt of $11.0M, resulting in net debt of $6.6M. Shareholders' equity stood at $3.9M, producing a debt-to-equity ratio of 2.82 and a current ratio of 1.03. Operating cash flow in FY2026 was -$4.5M, down from $7.4M in FY2025, while free cash flow reached -$5.0M. Capital expenditures totaled $564,000 in FY2026, and the company's share count decreased 4.5% over the past 5 years.

At $4.70 per share, Champions Oncology has a market capitalization of $65.4M and an enterprise value of $76.0M. The stock trades at a forward P/E of 22.9x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales multiple is 1.1x, below the peer median of 4.1x, while its EV/EBITDA of 189.1x exceeds the peer median of 12.0x. Over the past year, CSBR stock dropped 28.4%, while the SPY S&P 500 benchmark gained 16.8%. Over five years, the stock has declined 53.4% compared to an 83.0% gain for the S&P 500.

Wall Street analyst coverage includes a mean price target of $12.00, representing an upside of 155.3% over the last close of $4.70. For the current fiscal year ending April 30, 2026, EPS is estimated at $0.12, reflecting a projected decline of 68.0%. For the next fiscal year, 1 analyst projects revenue of $65.3M, representing 11.5% revenue growth, and an EPS of $0.10. Over the last four quarters, Champions Oncology has beaten EPS estimates 1 time.

This page is an AI-written research summary of Champions Oncology, Inc. (CSBR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CSBR income statement, CSBR balance sheet, CSBR key metrics, CSBR analyst forecast, CSBR chart. See the CSBR stock overview for the latest quote and news.